The Society of Obstetricians and Gynaecologists of Canada (SOGC) is aware of the recent shortage of the drug oxytocin in Canada and is working directly with Health Canada to ensure that there are proper recommendations that will address this issue.
It is our understanding that the oxytocin shortage will be short term and should not adversely effect the care of pregnant women. At this point it appears that all hospitals in Canada have sufficient supply to last until the next shipment is received. In the event that there is an unexpected increase in usage, affected hospitals are advised to contact Pfizer directly, for reallocation of the oxytocin available.
Once the SOGC has reviewed the situation with Health Canada, more comprehensive recommendations will be circulated, Recommendations will include alternate treatment options for labour induction, augmentation and postpartum haemorrhage prophylaxis including carbetocin and misoprostol. Prudent use of oxytocin in accordance with current guidelines is recommended in the interim.
Please feel free to share this information with your colleagues.